articleThe LancetDec 1, 2010Closed access

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Istituto di Ematologia di Bologna · Sapienza University of Rome · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

820
total citations
FWCI
40.91
Percentile
100%
References
40
Citations per year

Authors

21

Topics & keywords

Keywords
  • Medicine
  • Bortezomib
  • Multiple myeloma
  • Thalidomide
  • Dexamethasone
  • Autologous stem-cell transplantation
  • Regimen
  • Transplantation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.